AMELIORATE: early intensification in
AML
FLT3 mutations
acute myeloid leukemia
induction
peripheral blast clearance
risk stratification
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
14
7
2021
medline:
15
12
2021
entrez:
13
7
2021
Statut:
ppublish
Résumé
AMELIORATE is a Phase III, randomized trial aiming to personalize treatment intensity in Lay abstract The initial treatment of acute myeloid leukemia is called induction and aims to reduce significantly the number of leukemic cells in the bone marrow. In young adults, this phase comprises several agents, including conventional chemotherapy, monoclonal antibodies, and targeted drugs. Conventionally, induction is delivered as a single block of therapy, the response to which can be appreciated 3–4 weeks after its completion. The authors previously showed that the response to induction can be anticipated by the speed of disappearance of leukemic cells from peripheral blood after four days of therapy. In the AMELIORATE study, the authors aim to personalize the intensity of treatment based on this biomarker, by early intensification of treatment in patients who are predicted to have a poor response.
Autres résumés
Type: plain-language-summary
(eng)
Lay abstract The initial treatment of acute myeloid leukemia is called induction and aims to reduce significantly the number of leukemic cells in the bone marrow. In young adults, this phase comprises several agents, including conventional chemotherapy, monoclonal antibodies, and targeted drugs. Conventionally, induction is delivered as a single block of therapy, the response to which can be appreciated 3–4 weeks after its completion. The authors previously showed that the response to induction can be anticipated by the speed of disappearance of leukemic cells from peripheral blood after four days of therapy. In the AMELIORATE study, the authors aim to personalize the intensity of treatment based on this biomarker, by early intensification of treatment in patients who are predicted to have a poor response.
Identifiants
pubmed: 34254530
doi: 10.2217/fon-2021-0388
doi:
Substances chimiques
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
3787-3796Subventions
Organisme : Associazione Italiana Contro le Leucemie - Linfomi e Mieloma
ID : 5 × 1000 MIUR Ricerca Scientifica
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 5 × 1000 call project #21267